Biovica International AB (publ) announced the signing of an agreement providing access to DiviTum TKa to appropriate patients treated at a leading cancer center in Florida. This center in Florida is part of a large and well renowned organization that serves all 50 states in US and international representation as well. In total, the organization serves more than 1.3 million patients every year.

Florida being the third largest state and represents 6,5% of the US population. This organization already has a research collaboration with Biovica, resulting in several clinical trials that have been performed.